{
  "id": 15080295,
  "title": "Beam Therapeutics CEO John Evans sells $1.19m in company stock",
  "url": "https://urgent.news/2026/10/17/beam-therapeutics-ceo-john-evans-sells-1-19m-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T00:16:35.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/beam-therapeutics-ceo-john-evans-sells-119m-in-company-stock-93CH-4955042"
  },
  "original_language": "en",
  "account": "Beam Therapeutics CEO John Evans sold approximately $1.19 million worth of the company's stock on October 15 and 16, 2026. This was done through a pre-arranged Rule 10b5-1 trading plan. On the 15th, he exercised options to acquire an additional 25,000 shares at $1.03 each, then sold those shares the next day at prices between $23.23 and $23.84, resulting in a weighted average sale price of $23.566. The following day, Evans repeated the process, exercising options for 25,000 more shares at $1.03 and selling them at prices ranging from $23.66 to $24.56, with a weighted average sale price of $23.9838. The total shares traded over the two days amounted to 50,000, valued at $1,188,745. Following these transactions, Evans directly owns 1,047,205 shares of Beam Therapeutics common stock, with 103,000 shares held indirectly by his trust. The current stock price is $23.47, down 15% year-to-date, and the company's beta of 2.2 indicates high volatility typical of biotech stocks. Analysts note that Beam Therapeutics appears overvalued at its current price.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Ethos Technologies CEO sells over $4.6m in company stock",
        "url": "https://urgent.news/2026/10/16/ethos-technologies-ceo-sells-over-4-6m-in-company-stock",
        "published": "2026-10-16T22:16:11.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}